Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

(2012) Erika Hamilton et al.   Journal of Translational Medicine

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

(2012) Michael Untch et al.   LANCET ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients

(2011) Elizabeth A. Mittendorf et al.   CANCER

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-HER2 vaccines: new prospects for breast cancer therapy

(2010) Maha Zohra Ladjemi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

(2010) Håkan Norell et al.   Journal of Translational Medicine

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu–pulsed dendritic cell vaccines

(2009) Susan Bahl et al.   AMERICAN JOURNAL OF SURGERY

Results of the first phase 1 clinical trial of the HER-2/neupeptide (GP2) vaccine in disease-free breast cancer patients

(2009) Mark G. Carmichael et al.   CANCER

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2009) L. C. Benavides et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

(2009) P. P. Peethambaram et al.   CLINICAL CANCER RESEARCH

Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

(2009) B. Li et al.   CLINICAL CANCER RESEARCH

Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation

(2009) Leisha A. Emens et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

(2009) Mary L. Disis et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

(2009) Ritesh Patil et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Optimal dose and schedule of an HER-2/neu(E75) peptide vaccine to prevent breast cancer recurrence

(2008) Jarrod P. Holmes et al.   CANCER

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2008) Asna Amin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The E75 HER2/neu peptide vaccine

(2008) Elizabeth A. Mittendorf et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2008) G. E. Peoples et al.   CLINICAL CANCER RESEARCH

CD4+T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37)

(2008) Elizabeth A Mittendorf et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine

(2008) Jarrod P. Holmes et al.   JOURNAL OF CLINICAL ONCOLOGY